ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SAB Biotherapeutics’ SAB-185 shows activity against Omicron variant in study
December 20, 2021SAB Biotherapeutics has reported that its antibody SAB-185 for Covid-19 retained neutralisation activity against the Omicron variant of SARS-CoV-2 in an in vitro pseudovirus model. -
NIH trial to evaluate antibody therapy for Covid-19 treatment
April 23, 2021The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully human polyclonal antibody therapeutic called SAB-185 for treating Covid-19 in non-hospitalised individuals with mild or moderate ... -
SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185
August 14, 2020SAB Biotherapeutics, a US-based clinical-stage company, has dosed the first participant of a phase 1 study of SAB-185, its therapeutic candidate for Covid-19, in healthy volunteers.
Pharma Sources Insight January 2025
